Compare Amgen, Inc. (AMGN) vs VICI Properties Inc (VICI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs VICI Properties Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while VICI Properties Inc trades at $26.11 (market cap $28.64B). The key difference: Amgen, Inc. is far larger — about 6.8× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.92%). Which is the better fit depends on your goals.
| AMGN | VICI | |
|---|---|---|
Market Cap | $196.12B | $28.64B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $33.93 |
52-Week Low | $271.18 | $25.94 |
Enterprise Value | $241.41B | $45.86B |
Dividend Yield | 2.77% | 6.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VICI Properties trades at $26.01, showing modest daily gains. The stock is technically bearish with key support at $25, while fundamentals remain strong with a P/E of 8.91 and robust profitability margins. Recent news highlights concerns over tenant concentration but also underscores the REIT's investment-grade balance sheet and attractive 6.8% dividend yield. Q2 2026 earnings are anticipated on July 29, 2026.
The outlook is mixed: strong cash flows and analyst buy ratings support upside to a $30.75 target, but technical weakness and reliance on Caesars/MGM pose risks. Investors may find value in the discounted valuation if operational stability persists amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
